A Single-center, Open-label, Steady-state Drug-drug Interaction Study of SH229 Tablets and Daclatasvir Dihydrochloride Tablets in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Daclatasvir (Primary) ; SH-229 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Nanjing Sanhome Pharmaceutical
- 12 Aug 2019 Status changed from active, no longer recruiting to completed.
- 28 Nov 2018 Planned primary completion date changed from 19 Jan 2019 to 19 Dec 2018.
- 28 Nov 2018 Status changed from not yet recruiting to active, no longer recruiting.